- About Us
- Contact Us
03, November 2011
ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA
ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status o...
21, October 2011
ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger
ImmuPharma PLC (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon I...